These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 24219428)

  • 1. Safety of anti-tumor necrosis factor agents in psoriatic arthritis - an update.
    Palazzi C; D'Angelo S; Leccese P; Padula A; Olivieri I
    Expert Opin Drug Saf; 2014 Feb; 13(2):191-6. PubMed ID: 24219428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.
    Minozzi S; Bonovas S; Lytras T; Pecoraro V; González-Lorenzo M; Bastiampillai AJ; Gabrielli EM; Lonati AC; Moja L; Cinquini M; Marino V; Matucci A; Milano GM; Tocci G; Scarpa R; Goletti D; Cantini F
    Expert Opin Drug Saf; 2016 Dec; 15(sup1):11-34. PubMed ID: 27924643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.
    Tobin AM; Kirby B
    BioDrugs; 2005; 19(1):47-57. PubMed ID: 15691217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.
    Bonovas S; Minozzi S; Lytras T; González-Lorenzo M; Pecoraro V; Colombo S; Polloni I; Moja L; Cinquini M; Marino V; Goletti D; Matucci A; Tocci G; Milano GM; Scarpa R; Cantini F
    Expert Opin Drug Saf; 2016 Dec; 15(sup1):35-54. PubMed ID: 27924644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug persistence, effectiveness and safety assessment of anti-TNF therapies in psoriatic arthritis.
    Saad AA; Hyrich KL; Ashcroft DM
    Expert Opin Drug Saf; 2011 Mar; 10(2):219-26. PubMed ID: 21208138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TNF-alpha inhibitors for the six treatment targets of psoriatic arthritis.
    Lubrano E; Scriffignano S; Perrotta FM
    Expert Rev Clin Immunol; 2019 Dec; 15(12):1303-1312. PubMed ID: 31652079
    [No Abstract]   [Full Text] [Related]  

  • 7. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Benucci M; Gobbi FL; Guiducci S; Foti R; Mosca M; Goletti D
    Semin Arthritis Rheum; 2017 Oct; 47(2):183-192. PubMed ID: 28413099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease-modifying Antirheumatic Drugs (DMARD) and Combination Therapy of Conventional DMARD in Patients with Spondyloarthritis and Psoriatic Arthritis with Axial Involvement.
    Simone D; Nowik M; Gremese E; Ferraccioli GF
    J Rheumatol Suppl; 2015 Nov; 93():65-9. PubMed ID: 26523061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis.
    Roubille C; Richer V; Starnino T; McCourt C; McFarlane A; Fleming P; Siu S; Kraft J; Lynde C; Pope J; Gulliver W; Keeling S; Dutz J; Bessette L; Bissonnette R; Haraoui B
    Ann Rheum Dis; 2015 Mar; 74(3):480-9. PubMed ID: 25561362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis.
    Kerschbaumer A; Smolen JS; Dougados M; de Wit M; Primdahl J; McInnes I; van der Heijde D; Baraliakos X; Falzon L; Gossec L
    Ann Rheum Dis; 2020 Jun; 79(6):778-786. PubMed ID: 32381564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection.
    Caso F; Cantarini L; Morisco F; Del Puente A; Ramonda R; Fiocco U; Lubrano E; Peluso R; Caso P; Galeazzi M; Punzi L; Scarpa R; Costa L
    Expert Opin Biol Ther; 2015 May; 15(5):641-50. PubMed ID: 25652590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Agents other than Tumor Necrosis Factor Blockers in the Treatment of Psoriatic Arthritis.
    Atzeni F; Costa L; Caso F; Scarpa R; Sarzi-Puttini P
    J Rheumatol Suppl; 2015 Nov; 93():79-81. PubMed ID: 26523064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials.
    Saad AA; Symmons DP; Noyce PR; Ashcroft DM
    J Rheumatol; 2008 May; 35(5):883-90. PubMed ID: 18381787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging drugs for psoriatic arthritis.
    Caso F; Del Puente A; Peluso R; Caso P; Girolimetto N; Del Puente A; Scarpa R; Costa L
    Expert Opin Emerg Drugs; 2016; 21(1):69-79. PubMed ID: 26807876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis.
    Ash Z; Gaujoux-Viala C; Gossec L; Hensor EM; FitzGerald O; Winthrop K; van der Heijde D; Emery P; Smolen JS; Marzo-Ortega H
    Ann Rheum Dis; 2012 Mar; 71(3):319-26. PubMed ID: 21803753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Tumor Necrosis Factor-α Blockers in Psoriatic Disease. Therapeutic Options in Psoriatic Arthritis.
    Addimanda O; Possemato N; Caruso A; Pipitone N; Salvarani C
    J Rheumatol Suppl; 2015 Nov; 93():73-8. PubMed ID: 26523063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological agents in psoriatic arthritis.
    Kocijan R; Muschitz C; Rech J
    Wien Med Wochenschr; 2015 Jan; 165(1-2):36-9. PubMed ID: 25205184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis.
    Girolomoni G; Altomare G; Ayala F; Berardesca E; Calzavara-Pinton P; Chimenti S; Peserico A; Puglisi Guerra A; Vena GA
    Immunopharmacol Immunotoxicol; 2012 Aug; 34(4):548-60. PubMed ID: 22296031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs -- comparison of drugs and adverse reactions.
    Helliwell PS; Taylor WJ;
    J Rheumatol; 2008 Mar; 35(3):472-6. PubMed ID: 18203324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psoriatic arthritis.
    Wollina U; Unger L; Heinig B; Kittner T
    Dermatol Ther; 2010; 23(2):123-36. PubMed ID: 20415819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.